The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
In an effort to better alert the public of unlawful ingredients in dietary supplements, the FDA has created the Dietary Supplement Ingredient Advisory List, a new reference tool for consumers and manufacturers.
The final rule states that certain active ingredients are not allowed to be used in OTC hand sanitizers, which are meant for use without water and soap.
The Food and Drug Administration is requiring labeling changes for all opioid analgesics used in the outpatient setting, to provide additional guidance on safe opioid tapering. The changes will provide more information on how to safely decrease the dose in opioid-dependent patients. However, as the agency noted in a press release, “there is no standard…
The Food and Drug Administration (FDA) has issued warning letters to four homeopathic drug manufacturers due to serious concerns over the quality of the products produced by these companies.
Pharmacists, prescribers, and patients tend to have adequate knowledge of transmucosal immediate-release fentanyls for use in breakthrough cancer pain.
The Food and Drug Administration (FDA) has sent a second Complete Response Letter to Recro Pharma concerning their New Drug Application for intravenous meloxicam.
The Food and Drug Administration (FDA) issued a warning letter to NutraPharma, for selling false and misleading products that claim to treat addiction and chronic pain. The products are sold via the website nyloxin.com.
Allergan announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application for ubrogepant, a highly potent oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in adults.
